Search Results

recommendation. How should the medical community respond to this type of misleading marketing effort? We all need to understand the pervasiveness of conflicts of interest, especially financial, that exists in contemporary American medicine. We should very

will not benefit and who will succumb to the disease. Medical oncology can be seen as “a jealous mistress.” Our training reinforces innate workaholic tendencies, creating tension between work and a larger life with family and community. Physicians

, these programs have increasingly become established by community hospitals and private practices as well. This is an important evolution because these centers and practices are where most patients receive care. Over the past decade, models of care have

, these programs have increasingly become established by community hospitals and private practices as well. This is an important evolution because these centers and practices are where most patients receive care. Over the past decade, models of care have

significantly less likely to deem orders appropriate for older patients (OR: 0.97; CI: 0.96-0.98), urban patients (OR: 0.75; CI: 0.61-0.90), and patients with a history of breast MRI (OR: 0.66; CI: 0.54-0.81). Orders for patients from communities with median

oncologists throughout the U.S. (South [11], Northeast [7], West [6], Midwest [4]) completed the study questionnaire. Participating physicians represented private community practices (71%), hospital/academic affiliated practices (25%), and solo practice (4

geographically diverse, and includes more than 2.2 million US cancer patients (primarily treated in a community setting) from >280 cancer clinics. Results: First use of trastuzumab-anns was in early stage BC (eBC) and occurred 4 days after product launch. 2

resistance from the oncology community with baseline adherence rates ranging from 30-55%. Several factors contribute to this low uptake, including lack of access to pathway products, the cumbersome nature of pathway tools that generally have existed outside

the approval of immune checkpoint inhibitors (ICI) in 2015, and expansion to first-line (1L). We sought to assess the preferences of community hematologists/oncologists (cH/O) in 1L treatment for advanced NSCLC. Methods : Between June and August 2021

) and patient-reported outcomes (PROs). This study describes patient characteristics, treatment patterns, HCRU and PROs for these pts in community oncology settings. Methods: Retrospective medical records data from adults diagnosed with eSCLC between 1